About us

About us


Passionate about our work, inspired by what it can do

ANNAIDA was founded in 2018 by Marco and Gora – two friends bound by a shared passion for physics, microtechnology, and life sciences. The name stands for Anna and Ida – their two Italian grandmothers. They invented the MRS device using the microchip developed during their Ph.D. studies in Switzerland – at EPFL in Lausanne and the University of Fribourg.

Our vision

Annaida’s vision is to revolutionize how we measure, analyze and understand microscopic life using precise and non-invasive methods. MRS will create new opportunities for improvement of clinical outcomes, drug development, and scientific discovery. Annaida will continue investing resources and building knowledge to make the measurement and analysis of microscopic life easy, fast, and insightful.


Marco Grisi, PhD

CTO & co-founder

Marco pushes forward core technology and oversees development and research of Annaida. He co-founded Annaida after graduating, from the Swiss Federal Institute of Technology (EPFL) with a PhD in microengineering and microelectronics for NMR, because he recognizes the potential micro NMR technologies hold for the future.

Gora Conley, PhD

CEO & co-founder

Gora is responsible for driving public exposure efforts for Annaida. He obtained his PhD at the University of Fribourg (Switzerland), developing optical methods for synthetic and biological nanomaterials with a focus on project management and business development. After graduating, he co-founded Annaida with his lifelong friend Marco who shares his belief in the potential of micro NMR technologies.

Kathryn Marable, PhD


Kathryn is our R&D engineer, she is responsible for designing, constructing and testing the supporting electronics & mechanics on top of validating the performance of microchip sensors. Before joining Annaida, she completed a Ph.D. in experimental physics at Harvard University where she designed and constructed a cryogenic, radiofrequency antiproton trap in a strong magnetic field as part of the ATRAP collaboration at CERN.

Giulia Sivelli, PHD

R&D scientist

Giulia is our embryologist and R&D scientist, she is responsible for lab management, cell cultures, experimental design and data analysis. Giulia has a Master of Science in Molecular Biology of the Cell and a PhD from the Royal Veterinary College (London, UK) where she studied mesenchymal stem cells driven tissue regeneration. She has also completed a master course in human assisted reproductive techniques from Pompeu Fabra University in collaboration with EUGIN clinics (Barcelona, Spain).

Guillaume Gruet

R&D engineer

Guillaume is one of our R&D engineers. He participates in the development of our electronic test equipments and in the industrial design of EmbryoSpin. He has a Master of Science in Microengineering from EPFL (Lausanne, Switzerland) and a Minor in Energy.

Advisory Board

Fabien Murisier, PhD

Dr. Mursier is a senior clinical embryologist at ESHRE (European Society of Human Reproduction and Embryology). He is also the head of the Fertility sector at the Medisupport group, member of the CPMA management board and chief executive officer of the Fertas laboratory. Fabien oversees early stage development of new IVF technologies, all the way to clinical trials and commercialization. He received his PhD from the University of Lausanne before joining the Human Genetics Unit of the MRC in Edinburgh.

Prof. Kurt Wüthrich


Kurt Wüthrich is a Professor of Biophysics at the ETH Zürich, and Distinguished Senior Professor at the iHuman Institute, ShanghaiTech University. For 50 years, Wüthrich groups at the ETH Zürich, at Scripps Research and at the iHuman Institute have used nuclear magnetic resonance spectroscopy (NMR) for research in structural biology. Contributions include the method of protein structure determination with NMR in solution, and the use of the principles of transverse relaxation-optimized spectroscopy (TROSY) for NMR experiments with large supramolecular assemblies. Kurt Wüthrich’s achievements in the sciences have been recognized by the Prix Louis Jeantet de Médecine, the Kyoto Prize in Advanced Technology, the Nobel Prize in Chemistry, and by a number of other awards and honorary degrees.

Riccardo Tediosi, PhD


Dr. Tediosi is a senior executive with a strong background in instrument development and in startup-scaleup ventures. He holds an executive MBA from IMD Business school and combines technical management background with sound business management practices. He is currently CTO at QualySense AG developing AI-based robotic platforms for contactless characterization of seeds. He has been R&D director at Bruker Biospin for the development of NMR/MRI probeheads for high-end MR systems. He holds a PhD in Solid State Physics at the University of Geneva after obtaining his Master degree in Photonics in Pavia.

Prof. Barry Behr


Prof. Barry Behr is a nationally and internationally renowned clinical and scientific leader in the research and advances of human reproduction. As a world-renown scientist and lecturer, he is highly sought after to chair scientific programs and conferences and is the first non MD President of the Pacific Coast Reproductive Society to be appointed as program chairman of several professional meetings. He is the director of the IVF/ART laboratory at Stanford University and is the Faculty Advisor for the Transgenic, Knockout and Tumor Model Center. In the 90’s Dr. Behr developed a culture medium for embryo culture to the blastocyst stage, which has improved pregnancy rates, implantation rates and reduced the risks of multiple gestation in IVF. He is also the co-inventor of an embryo selection technology that was featured in Time Magazine’s Best of Everything as 8th place in the top 10 Medical Breakthroughs of 2010.

Board of Directors

Rita Vassena



Rita Vassena, co-founder and CEO of Fecundis, previously served as the Global Scientific Director of the EUGIN Group until 2022, overseeing an international network of centers for human infertility treatment, serving more than 40.000 patients a year. She is also an educator in the field, teaching in the Master in Human Assisted Reproductive Technologies and the Master of Translational Medicine in Barcelona.

Dr. Vassena is involved in evaluating projects for funding agencies like FWO (Belgium) and the European Commission (EIC Accelerator). She sits on the scientific advisory boards of various infertility and women’s health companies in Europe and North America. With over 120 co-authored research papers in esteemed journals, she has held leadership roles in ESHRE, the largest scientific society for human infertility, and has been a member of the Executive Board of SEF, the Spanish Fertility Society, since 2021.

Pascal Winnen


Pascal is a co-founder and the CEO of HEMEX, a pharmaceutical, biotech and medical device consulting firm with offices in Switzerland, Germany and the USA. Previously he worked for Finox Biotech, bringing one of the first biosimilar fertility treatments to the market in the EU and leading to the successful acquisition by Gedeon Richter for EUR 190 million in 2016.

Jacqueline Ruedin Rüsch


Jacqueline is a seasoned entrepreneur and an influential leader with over 25 years of experience. She started her career in the banking sector and founded her first company in 2011. Soon after she started investing in venture capital and became an vc investor in seed and early-stage companies. Now She serves on several boards as a member or as the chairperson.

She recently launched a fund that targets gender balance teams. She strongly believes that more diversity and inclusion are not only good for society but also a very rewarding investment case with a strong social impact. As a passionate public speaker, she captivates audiences with her empathic style, engaging with participants on the topic.

She believes that giving back and caring is the only way to move things forward.

Quality Policy

ANNAIDA is pioneering a new non-invasive technology to investigate the chemistry inside microscopic life while maintaining its full integrity. We are dedicated to analysing cellular life and better understanding its metabolic fingerprint. The unprecedented scale of our device allows for a precise understanding of cells ranging from embryos to stem-cell organoids and much more.
ANNAIDA’s Quality Policy is focused on the pursuit of Customer and Interested Parties satisfaction, trust, and loyalty, as well as on full compliance with mandatory regulations/laws. It considers the internal and external context in which the Company operates, monitoring its performance and drawing inspiration from it for the definition of objectives, for continuous improvement and risk assessment in the process’s execution.

To make this possible, the Quality Policy Annaida has established, documented, implemented, maintained, and continually improves, in accordance with the requirements of ISO 9001:2015, specifically addresses all internal and external activities, and business, necessary to ensure Annaida’s success, focusing on the following aspects:

1. Customer Focus: Our first priority is to understand the needs and expectations of our customers and to meet or exceed them. We continuously strive to improve our customer satisfaction by providing quality products and services that meet their requirements.

2. Leadership: Our senior management is committed to the implementation and improvement of our QMS, and they lead by example in promoting quality as a fundamental aspect of our business activities.

3. Engagement of People: We recognize the importance of our employees in achieving our quality objectives and strive to provide a supportive and inclusive work environment that promotes individual growth and development.

4. Process Approach: We believe that processes are essential to the achievement of our quality objectives and we use a process approach to plan, design, implement, and improve our processes.

5. Continual Improvement: We are committed to continually improving our QMS and our products and services. We establish quality objectives and review our performance to determine areas for improvement.

6. Evidence-based Decision Making: We use data and information from our QMS to make informed decisions that enhance our ability to achieve our quality objectives.

7. Relationship Management: We strive to establish and maintain positive relationships with our suppliers, customers, and other stakeholders, recognizing that their success is key to our success.

We believe that a strong Quality Management System plays a significant role in helping us to achieve our ambitions, ensuring that ANNAIDA develop its place as leading worldwide company.
This policy is communicated, understood, and followed by all employees and is reviewed for continued suitability at least annually, during the management review.

They’re part of our story:


They’re part of our story: